ABOUT
The only North American contrast media manufacturer building a secure, cost advantaged and vertically integrated contrast media drug solution.
Two Discoveries, One Supply Chain
Brent and Brad Willis started exploring for minerals alongside their father at just 17 years old, five mining ventures deep before they turned 30. What struck them wasn’t the ore, but how fragile the supply chain above it was. Every barium and iodine contrast scan performed in North America depends on foreign imports and synthetic barium, with no domestic backup.
In 2017, the brothers founded Voyageur Pharmaceuticals to remove that single point of failure. Today, the company owns 100% of Frances Creek, one of the purest known natural barium deposits in the world, confirmed at 98.8%+ pharmaceutical-grade purity at a 90%+ lower cost than synthetic alternatives1,1.1. Alongside it, the Mueller Process unlocks a domestic iodine source from oilfield brine that has, until now, simply been discarded as waste. Voyageur is building North America’s first vertically integrated contrast media supply chain.
90% Barium Cost Advantage
One of the purest known natural barium deposits in the world, confirmed at 98.8%+ pharmaceutical-grade purity and a 90%+ lower cost than synthetic alternatives1,1.1.
Patent Pending Iodine Extraction Technology
Patent-pending technology extracts pharmaceutical-grade iodine from oilfield brine water currently discarded as waste by the oil industry for cost–effective, pharmaceutical grade iodine contrast media.
Voyageur Leadership
Voyageur’s leadership combines the mining engineering expertise that discovered and advanced the Frances Creek barite deposit with corporate finance leadership from Lafarge and medical-device commercialisation experience: a team with a track record of moving resource discoveries from exploration through to cash-flowing production.
Brent Willis
Brad Willis
Albert Deslauriers
Ethan Mohan
Board of Directors
Voyageur’s Board pairs deep capital markets experience with decades of pharmaceutical and life sciences leadership. Directors include veterans of US IPOs, Fortune 100 risk management, and multi-billion-dollar corporate banking bringing the financial rigor and industry insight needed to guide Voyageur through its next phase of growth.
Eugene (Gene) Fritzel
Eric S Pommer
Kevin McBeth
Beth Shaw
Christopher Van Buren
Jeffrey Kraws
Virginia Alling
Scientific Advisory Board
Voyageur’s Scientific Advisory Board brings leading radiology and imaging expertise from institutions including the Mayo Clinic, and Evangelisches Krankenhaus Düsseldorf. Established in 2021, the board guides clinical validation of Voyageur’s barium and iodine contrast media, ensuring every product meets rigorous imaging and safety standards.
Dr. Iryna Saranchova
Dr. Ibrahim Hashmi
Brian Mueller
Kyle Peterson
Feasibility Pipeline
2022NI 43-101 PEA completed
Independent study by SGS Canada confirmed the Frances Creek resource and production economics.
Q3 2024Alberta Innovates $600K grant received
Non-dilutive government funding secured for natural vs. synthetic barium product performance studies and the AICE-Market Access Programme.
Q3 2024Human clinical testing completed and clinically accepted
Two-phase testing programme initiated to evaluate clinical safety, imaging quality, and operational efficiency.
Q3 2024Five Health Canada-licensed barium contrast products introduced
SmoothX, SmoothHD, SmoothLD, VisionHD, and VisionLD launched after 18 months of research and development.
Q4 2026Frances Creek Pre-feasibility study
NI 43-101 Pre-Feasibility Study advancing the 2022 PEA, incorporating updated barite grade, purity, and commercial sales data for the Frances Creek barium project.
Q4 2026Iodine Drug Manufacturing FEL-3 study (internal)
Internal engineering study integrating the Mueller iodine extraction process with the Streamline manufacturing platform, advancing toward a demonstration-scale design.
Q1–Q2 2027Frances Creek Final feasibility study
NI 43-101 Final Feasibility Study incorporating geotechnical drilling and quarry pit design data to finalize the Frances Creek barium project's economics and plant design.
Q2–Q3 2027Bayer Iodine Production Project FEL-3 study
Fluor-led feasibility study, backed by US$2.35M in Bayer milestone funding, for an iodine extraction and production facility in Oklahoma using Voyageur's patent-pending Mueller process.
Q3–Q4 2027Barium & Iodine Drug Manufacturing Facility, USA FEL-3 study
Fluor-led feasibility study for an integrated GMP facility combining Frances Creek barite with Oklahoma-sourced iodine into finished barium and iodine contrast drugs.
Go-To-Market Timeline Forecast
2028-29Frances Creek barite mine in full production
Commercial-scale, pharmaceutical-grade Barium contrast drug production in North America; full operations subject to capex financing.
2028-29Bayer Iodine Production Project
Exclusive rights to negotiate potential long-term offtake agreement, subject to successful FEL-3 feasibility completion and negotiation of definitive terms.
2030Voyageur Iodine Contrast Drug Production
First vertically integrated domestic iodine producer in a 100% import-dependent category.4
2030+Global Barium and Iodine Contrast Market Disruption
Domestic supply, management-expected significant cost advantage and FDA approval to disrupt the current industry oligopoly.
News
Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
Voyageur Announces Closing of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption
Voyageur Announces Filing of Amended and Restated Offering Document
Voyageur Announces Update to Non-Brokered Life Offering
Voyageur Announces Shares for Debt Settlement and Stock Option Repricing
Voyageur Announces Non-Brokered Life Offering
Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU Grants, and Proposed Issuance of Securities for Debt
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with Phalanx
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
Voyageur Advances Frances Creek Barite Project with Vast Engagement for Bulk Sample Permit
Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants
Voyageur Pharmaceuticals Signs Loi For Latin America Distribution Partnership Supporting Global Market Expansion
Voyageur And Altillion Forge Landmark Alliance To Establish NorthAmerica’s First Vertically Integrated Iodine Drug Supply Chain
Voyageur Enters Revenue Stage With First Commercial Sale of Barium Contrast Agents
Voyageur Pharmaceuticals Announces Appointment Of Ethan Mohan As Executive Vice President
Voyageur Pharmaceuticals Announces Changes To Board Of Directors And DSU Grant
Voyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study Results
Voyageur Pharmaceuticals Grants Deferred Share Units
Voyageur Completes Human Testing Of Barium Contrast Products And Prepares For Canadian Market Launch
Voyageur Pharmaceuticals Advances Frances Creek Project, Paving The Way For A Secure, Vertically Integrated Barium Contrast Product Line
Voyageur Clarifies Terms Of Previously Announced Agreement
Voyageur Pharmaceuticals Grants Deferred Share Units
Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes
Voyageur Advances MRI Drug Development Using Next-Generation Endohedral Fullerenes
Voyageur Receives $600k Grant From Alberta Innovates for Product Development
Voyageur Secures $687k of Additional Capital From Warrant Exercises
Voyageur Recaps Significant 2024 Achievements And Unveils Plans For Transformational 2025, Including Market Launch For Barium Suite Of Products And Advancement Of Iodine Suite
Voyageur Commences Testing Of Innovative Barium Contrast Product Line In Human Radiology Scans, Paving The Way for Near-Term Market Launch
Voyageur Pharmaceuticals Ltd. Signs Letter Of Intent With Global Contrast Imaging Company To Expand Market Reach And Product Portfolio
Voyageur Announces Closing Of Final Tranche Of Private Placement
Voyageur Announces Closing Of First Tranche Of Private Placement
Voyageur Announces Extension to Complete Proposed Private Placement
Voyageur Announces Proposed Private Placement
Voyageur Pharmaceuticals Grants Stock Options
Voyageur Pharmaceuticals Strengthens Leadership Team with Strategic Appointment of Dr. Ibrahim Hashmi as VP of Business Development
Voyageur Pharmaceuticals Appoints Dr. Iryna Saranchova as Chief Science Officer, Enhancing the Company’s Research and Innovation Leadership
Voyageur Pharmaceuticals Grants Deferred Share Units
Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry
